Last reviewed 2026-05-28 · How we verify

ETC-1922159

EDDC (Experimental Drug Development Centre), A*STAR Research Entities · Phase 1 active Small molecule ✓ Verified May 2026 Quality 10/100

ETC-1922159 is a Small molecule drug developed by EDDC (Experimental Drug Development Centre), A*STAR Research Entities. It is currently in Phase 1 development.

ETC-1922159 is a small molecule being studied in combination with pembrolizumab for the treatment of advanced MSS/pMMR ovarian cancer. It is also being investigated in combination with pembrolizumab and denosumab/zoledronic acid for the treatment of solid tumors and platinum-resistant ovarian cancer.

Likelihood of approval

9.6% vs 9.6% industry baseline

If approved by FDA: likely 2033–2036

Steps remaining: Phase 2 → Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 1 → approval rate +9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2033–2036	—
EMA	EU	2034–2037	+0.7 yr
MHRA	GB	2034–2037	+0.7 yr
Health Canada	CA	2034–2038	+0.9 yr
TGA	AU	2034–2038	+1.2 yr
PMDA	JP	2034–2038	+1.5 yr
NMPA	CN	2035–2039	+2.3 yr
MFDS	KR	2034–2038	+1.4 yr
CDSCO	IN	2034–2039	+1.8 yr
ANVISA	BR	2035–2039	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	ETC-1922159
Sponsor	EDDC (Experimental Drug Development Centre), A*STAR Research Entities
Modality	Small molecule
Phase	Phase 1

Approved indications

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

ETC-1922159 CI brief — competitive landscape report
ETC-1922159 updates RSS · CI watch RSS
EDDC (Experimental Drug Development Centre), A*STAR Research Entities portfolio CI

Frequently asked questions about ETC-1922159

What is ETC-1922159?

ETC-1922159 is a Small molecule drug developed by EDDC (Experimental Drug Development Centre), A*STAR Research Entities.

Who makes ETC-1922159?

ETC-1922159 is developed by EDDC (Experimental Drug Development Centre), A*STAR Research Entities (see full EDDC (Experimental Drug Development Centre), A*STAR Research Entities pipeline at /company/eddc-experimental-drug-development-centre-a-star-research-entities).

What development phase is ETC-1922159 in?

ETC-1922159 is in Phase 1.

Manufacturer: EDDC (Experimental Drug Development Centre), A*STAR Research Entities — full pipeline

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing